A bill to authorize the National Science Foundation to conduct research for biotechnology risk assessment, and for other purposes.
SB 2697, titled the National Biotechnology Safety Act, would create a National Science Foundation research program focused on biotechnology risk assessment. The bill directs NSF to fund research on organisms produced with biotechnology and their introduction into the environment, with an emphasis on environmental, human health, and animal health risks. It also prioritizes studies on unintended genetic changes, monitoring dispersal and persistence, gene transfer, management practices to reduce risk, comparisons with conventional organisms and other human activities, and potential interactions between biotechnology, artificial intelligence, and other emerging technologies.
The bill also requires NSF to contract with the National Academies of Sciences, Engineering, and Medicine to conduct a two-phase study on the safety and benefits of biotechnology. Phase one would compare biotechnology tools to conventional methods and recommend risk-proportionate regulatory frameworks; phase two would examine commercialized and emerging biotechnology products, recommend ways to reduce or remove biotechnology-specific oversight when appropriate, and identify remaining research gaps. NSF would then submit an implementation plan to Congress for federal research, development, and demonstration activities to address those gaps.
If enacted, the bill would expand NSF’s role in biotechnology safety research and create a formal federal research program within the Directorate for Technology, Innovation, and Partnerships. It would authorize $50 million annually for fiscal years 2026 through 2030 for the research program, plus $1.5 million for the National Academies study in fiscal year 2026. The bill would not directly amend existing regulatory statutes, but it would influence how federal agencies such as USDA, FDA, and EPA evaluate biotechnology products by generating research and recommendations intended to support clearer, risk-based regulatory pathways.
Based on the bill text and available context, the measure appears broadly supportive of biotechnology while emphasizing safety, oversight, and regulatory clarity. The findings frame biotechnology as important across agriculture, medicine, industry, and defense, and the bill’s structure suggests a bipartisan, research-oriented approach rather than a restrictive one. No committee transcript or vote record is available, so there is no documented opposition or support beyond the introduction and referral stage.
The main policy tension in the bill is between encouraging biotechnology innovation and ensuring adequate oversight of potential environmental, human, and animal health risks. The bill’s research priorities reflect concern about unintended genetic effects, gene drives, gene transfer, and the convergence of biotechnology with artificial intelligence, which could be points of concern for critics worried about ecological or public health impacts. At the same time, the bill explicitly seeks pathways to reduce or remove biotechnology-specific oversight for products that do not pose greater risk than conventional alternatives, which may be a point of concern for advocates of stronger regulation who fear premature deregulation.